Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 3/20 | 0.38 |
| ▸ | CDK8 | P49336 | 3/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21072297 | 0.77 | AXL (0.51) | CCNCCDK8BRD4 | |
| SCHEMBL23916015 | 0.74 | LRRK2 (0.43) | PDE3BPDE3A | |
| SCHEMBL14217428 | 0.74 | ALDH1A1 (0.34) | — | |
| SCHEMBL23916420 | 0.73 | HPGDS (0.36) | PDE3BPDE3A | |
| SCHEMBL23915989 | 0.73 | PDE3B (0.31) | PDE3BPDE3A | |
| SCHEMBL23909958 | 0.72 | IRAK4 (0.42) | ERCC1ERCC4CCNCCDK8PDE3B | |
| SCHEMBL20329401 | 0.72 | KDM4E (0.49) | — | |
| SCHEMBL427409 | 0.72 | CHEK1 (0.45) | ERCC1ERCC4CDK8IRAK4MPO | |
| SCHEMBL30431594 | 0.72 | CHEK1 (0.45) | ERCC1ERCC4CDK8IRAK4MPO | |
| SCHEMBL20329237 | 0.72 | MAPT (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | ERCC1 4143/4885ERCC4 3637/4885CCNC 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.